Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Revenue, Cost of Revenues, and Expense

The following table summarizes the Company’s proportionate share of the activity under the Biogen Collaboration Agreement:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025		2025
	(unaudited)
Collaboration revenue (ZURZUVAE)	$	20,164	$	20,164
Cost of revenues	434		434
Research and development expenses	(928)		(928)
Selling, general and administrative expenses	13,561		13,561